Devel­op­ment of Bio­log­i­cal Drugs for Onco­log­i­cal Indi­ca­tions at Mabion

The high attri­tion rates observed in ear­ly-stage oncol­o­gy bio­log­ics devel­op­ment under­score per­sis­tent gaps in trans­la­tion­al and process sci­ences that com­pro­mise pro­gres­sion from dis­cov­ery to clin­i­cal eval­u­a­tion. Com­bin­ing data from pub­lished lit­er­a­ture, clin­i­cal tri­al reg­istries, reg­u­la­to­ry case exam­ples, and meta-analy­ses of devel­op­ment out­comes, we sys­tem­at­i­cal­ly iden­ti­fied and cat­e­go­rized pre­dom­i­nant fail­ure modes affect­ing ther­a­peu­tic bio­log­ics, includ­ing mon­o­clon­al anti­bod­ies and engi­neered pro­tein modalities.

Fail­ure path­ways were strat­i­fied into:

    • bio­log­i­cal-tar­get mischaracterization,
    • prod­uct devel­opa­bil­i­ty and man­u­fac­tur­ing liabilities,
    • clin­i­cal trans­la­tion challenges.

A notable instance illus­trat­ing tar­get selec­tion fail­ure is matuzum­ab, a human­ized anti-EGFR anti­body whose devel­op­ment was halt­ed after dis­ap­point­ing effi­ca­cy in phase II col­orec­tal can­cer tri­als despite promis­ing pre­clin­i­cal ratio­nale, reflect­ing defi­cien­cies in trans­lat­ing mech­a­nis­tic under­stand­ing into clin­i­cal ben­e­fit. Sim­i­lar­ly, depatux­izum­ab mafodotin, an EGFR-tar­get­ed anti­body-drug con­ju­gate, ceased enrol­ment due to lack of antic­i­pat­ed clin­i­cal activ­i­ty in glioblas­toma, exem­pli­fy­ing trans­la­tion­al attri­tion root­ed in tar­get modal­i­ty and mod­el pre­dic­tiv­i­ty. In the domain of immuno­genic and phar­ma­co­ki­net­ic lia­bil­i­ties, fail­ure to ade­quate­ly assess or mit­i­gate immuno­genic respons­es and devel­opa­bil­i­ty issues remains a recur­rent imped­i­ment, as evi­denced by the foun­da­tion­al risk analy­ses in bio­log­ics devel­op­ment and immuno­genic­i­ty literature.

Quan­ti­ta­tive syn­the­sis fur­ther indi­cates that ear­ly devel­opa­bil­i­ty screen­ing, bio­phys­i­cal pro­fil­ing, and inte­gra­tion of pre­dic­tive bio­log­i­cal mark­ers are crit­i­cal to de-risk can­di­dates before cost­ly clin­i­cal invest­ments. These find­ings sug­gest that enhanced inte­gra­tion of mech­a­nis­tic phar­ma­col­o­gy, CMC sci­ence, and pre­dic­tive bio­mark­er frame­works could reduce fail­ure rates, expe­dite trans­la­tion­al deci­sion-mak­ing, and align ear­ly-stage oncol­o­gy bio­log­ics with pre­ci­sion med­i­cine objectives.

Development of Biological Drugs for Oncological Indications at Mabion
Development of Biological Drugs for Oncological Indications at Mabion
Development of Biological Drugs for Oncological Indications at Mabion

Jakub Knurek

Jakub Knurek is a mar­ket­ing spe­cial­ist at Mabion Bio­log­ics with exper­tise in biotech and phar­ma mar­ket­ing. His work focus­es on trans­lat­ing bio­log­ics devel­op­ment, drug man­u­fac­tur­ing, and ana­lyt­i­cal ser­vices into clear, val­ue-dri­ven com­mu­ni­ca­tion that sup­ports busi­ness devel­op­ment, brand dif­fer­en­ti­a­tion, and mar­ket visibility.

With a sci­en­tif­ic foun­da­tion in bio­log­ics and expe­ri­ence relat­ed to ana­lyt­i­cal method trans­fer dur­ing Mabion’s col­lab­o­ra­tion with Novavax, as well as expo­sure to mon­o­clon­al anti­bod­ies such as rit­ux­imab and cetux­imab, Jakub bridges sci­en­tif­ic under­stand­ing with strate­gic com­mu­ni­ca­tion. In his pre­sen­ta­tion, “Devel­op­ment of Bio­log­i­cal Drugs for Onco­log­i­cal Indi­ca­tions at Mabion,” he will share insights into Mabion’s role in sup­port­ing the devel­op­ment and man­u­fac­tur­ing of bio­log­ic drug can­di­dates for oncology.

Vis­it our web­site.

Jakub cur­rent­ly leads Mabion’s mar­ket­ing activ­i­ties across dig­i­tal chan­nels, con­tent, events, and indus­try com­mu­ni­ca­tions. His expe­ri­ence includes strength­en­ing Mabion’s pres­ence in glob­al biotech and phar­ma mar­kets through sci­en­tif­ic con­tent, indus­try media, LinkedIn com­mu­ni­ca­tion, SEO, and par­tic­i­pa­tion in inter­na­tion­al events includ­ing CPHI and BIO Inter­na­tion­al Con­ven­tion. He was nom­i­nat­ed as a Future Leader in the CPHI Phar­ma Awards in 2024 and 2025, and as One-to-Watch and Mar­ket­ing Pro­fes­sion­al of the Year at the Life Sci­ence Sales and Mar­ket­ing Awards 2025.

More about Jakub Knurek.

With a sci­en­tif­ic foun­da­tion in bio­log­ics and expe­ri­ence relat­ed to ana­lyt­i­cal method trans­fer dur­ing Mabion’s col­lab­o­ra­tion with Novavax, as well as expo­sure to mon­o­clon­al anti­bod­ies such as rit­ux­imab and cetux­imab, Jakub bridges sci­en­tif­ic under­stand­ing with strate­gic com­mu­ni­ca­tion. In his pre­sen­ta­tion, “Devel­op­ment of Bio­log­i­cal Drugs for Onco­log­i­cal Indi­ca­tions at Mabion,” he will share insights into Mabion’s role in sup­port­ing the devel­op­ment and man­u­fac­tur­ing of bio­log­ic drug can­di­dates for oncology.

Vis­it our web­site.

Jakub cur­rent­ly leads Mabion’s mar­ket­ing activ­i­ties across dig­i­tal chan­nels, con­tent, events, and indus­try com­mu­ni­ca­tions. His expe­ri­ence includes strength­en­ing Mabion’s pres­ence in glob­al biotech and phar­ma mar­kets through sci­en­tif­ic con­tent, indus­try media, LinkedIn com­mu­ni­ca­tion, SEO, and par­tic­i­pa­tion in inter­na­tion­al events includ­ing CPHI and BIO Inter­na­tion­al Con­ven­tion. He was nom­i­nat­ed as a Future Leader in the CPHI Phar­ma Awards in 2024 and 2025, and as One-to-Watch and Mar­ket­ing Pro­fes­sion­al of the Year at the Life Sci­ence Sales and Mar­ket­ing Awards 2025.

More about Jakub Knurek.

Jakub Knurek | Development of Biological Drugs for Oncological Indications at Mabion
Jakub Knurek, Mabion, POLAND

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy

PORT for Busi­ness — Com­pa­ny Session